London-based Livanova plc has agreed to acquire Tandemlife for $200 million up front and up to an additional $50 million in regulatory milestones. The Pittsburgh-based startup has an FDA cleared and CE marked short-term extracorporeal circulatory support platform, which it said is the world's first. Tandemlife's four products are for hospital use and are designed around a single pump and controller. The deal is slated to close during the first half of this year. Read More
